| Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. | |
| | |
MedLine Citation:
|
PMID: 11112955 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The object of this clinical experience was to evaluate the correlation between pericranial botulinum toxin type A (BOTOX, Allergan Corp, Irvine, CA) administration and alleviation of migraine headache symptoms. Study Design and Setting: A nonrandomized, open-label study was performed at 4 different test sites. The subjects consisted of 106 patients, predominantly female, who either (1) initially sought BOTOX treatment for hyperfunctional facial lines or other dystonias with concomitant headache disorders, or (2) were candidates for BOTOX treatment specifically for headaches. Headaches were classified as true migraine, possible migraine, or nonmigraine, based on baseline headache characteristics and International Headache Society criteria. BOTOX was injected into the glabellar, temporal, frontal, and/or suboccipital regions of the head and neck. Main outcome measures were determined by severity and duration of response. The degrees of response were classified as: (1) complete (symptom elimination), (2) partial > or =50% reduction in headache frequency or severity), and (3) no response [neither (1) nor (2)]. Duration of response was measured in months for the prophylactic group. RESULTS: Among 77 true migraine subjects treated prophylactically, 51% (95% confidence interval, 39% to 62%) reported complete response with a mean (SD) response duration of 4.1 (2.6) months; 38% reported partial response with a mean (SD) response duration of 2.7 (1.2) months. Overall improvement was independent of baseline headache characteristics. Seventy percent (95% confidence interval, 35% to 93%) of 10 true migraine patients treated acutely reported complete response with improvement 1 to 2 hours after treatment. No adverse effects were reported. CONCLUSIONS: BOTOX was found to be a safe and effective therapy for both acute and prophylactic treatment of migraine headaches. Further research is needed to explore and develop the complete potential for the neuroinhibitory effects of botulinum toxin. |
| | |
Authors:
|
W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda |
Related Documents
:
|
9918345 - Movement and reaction times and fine coordination tasks following pallidotomy. 21468625 - Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on hba1c bloo... 21339805 - The use of mitomycin c with autologous limbal-conjunctival autograft transplantation fo... 10410185 - Naratriptan: an alternative for migraine. 1743335 - Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients ... 1430925 - Endoscopic carpal tunnel release. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery Volume: 123 ISSN: 0194-5998 ISO Abbreviation: Otolaryngol Head Neck Surg Publication Date: 2000 Dec |
Date Detail:
|
Created Date: 2000-12-20 Completed Date: 2001-01-04 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8508176 Medline TA: Otolaryngol Head Neck Surg Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 669-76 Citation Subset: IM |
Affiliation:
|
University of California, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adult Aged Botulinum Toxin Type A / pharmacology, therapeutic use* Female Humans Male Middle Aged Migraine Disorders / classification, diagnosis, drug therapy*, prevention & control Neuromuscular Agents / pharmacology, therapeutic use* Pain Measurement Questionnaires Severity of Illness Index Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Botulinum Toxin Type A; 0/Neuromuscular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Air pollution and emergency hospital admissions for cardiovascular diseases in Valencia, Spain.
Next Document: Apoptosis in the developing human cricoid cartilage: a pilot study.